OverviewSuggest Edit

BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We are utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on our own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. Our development strategy focuses on utilization of the Food and Drug Administration's (FDA's) 505(b)(2) approval process. This regulatory pathway allows us to potentially obtain more timely and efficient approval of new formulations of previously approved therapeutics. Our particular area of focus is the development and commercialization of products in the areas of pain management and addiction medicine. These are areas where we believe our drug delivery technologies and products can best be applied to address critical unmet medical needs. Our marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. We look to improve upon existing drugs by enhancing their efficacy and/or ease of administration, or create new therapies, all with the ultimate goal of enhancing patient care.
TypePublic
Founded1997
HQRaleigh, US
Websitebdsi.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Mar 2019)164(+43%)
Revenue (FY, 2019)$111.4 M(+101%)
Share Price (May 2020)$4.8

Key People/Management at BioDelivery Sciences International

Peter S. Greenleaf

Peter S. Greenleaf

Chairman
Herm Cukier

Herm Cukier

Chief Executive Officer, Director
Scott Plesha

Scott Plesha

President and Chief Commercial Officer
Todd C. Davis

Todd C. Davis

Director
Terry Coelho

Terry Coelho

Chief Financial Officer
Joseph Lockhart

Joseph Lockhart

Senior Vice President, Operations
Show more

BioDelivery Sciences International Office Locations

BioDelivery Sciences International has an office in Raleigh
Raleigh, US (HQ)
4131 Parklake Ave #225
Show all (1)

BioDelivery Sciences International Financials and Metrics

BioDelivery Sciences International Revenue

Embed Graph
View revenue for all periods
BioDelivery Sciences International's revenue was reported to be $111.39 m in FY, 2019
USD

Revenue (Q1, 2020)

38.3m

Gross profit (Q1, 2020)

32.7m

Gross profit margin (Q1, 2020), %

85.5%

Net income (Q1, 2020)

5.0m

EBIT (Q1, 2020)

6.0m

Market capitalization (28-May-2020)

478.5m

Closing stock price (28-May-2020)

4.8

Cash (31-Mar-2020)

70.6m

EV

466.5m
BioDelivery Sciences International's current market capitalization is $478.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.3m54.5m11.4m38.9m48.2m15.5m62.0m55.6m111.4m

Revenue growth, %

243%24%(68%)

Cost of goods sold

1.8m1.9m2.1m4.9m8.1m11.3m19.5m15.8m21.6m

Gross profit

1.5m52.6m9.3m34.0m40.1m4.3m42.5m39.9m89.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

10.8m63.2m23.2m70.5m83.6m32.0m21.2m43.8m63.9m

Accounts Receivable

101.1k520.8k2.8m3.1m2.5m3.6m8.9m13.6m38.8m

Prepaid Expenses

229.9k226.1k630.7k2.9m3.9m3.6m3.2m3.8m

Inventories

1.8m2.6m3.4m6.1m5.4m11.3m
USDY, 2020

EV/EBIT

78 x

EV/CFO

73 x

Financial Leverage

2.6 x
Show all financial metrics

BioDelivery Sciences International Online and Social Media Presence

Embed Graph

BioDelivery Sciences International News and Updates

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioDelivery Sciences International, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, July 29, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of BioDelivery Sciences International, Inc....

BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock

RALEIGH, N.C., April 11, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced the pricing of an underwritten public offering by the Company and a selling stockholder of 12,000,000 shares of common stock at a public offering pric…

BioDelivery Sciences International Frequently Asked Questions

  • When was BioDelivery Sciences International founded?

    BioDelivery Sciences International was founded in 1997.

  • Who are BioDelivery Sciences International key executives?

    BioDelivery Sciences International's key executives are Peter S. Greenleaf, Herm Cukier and Scott Plesha.

  • How many employees does BioDelivery Sciences International have?

    BioDelivery Sciences International has 164 employees.

  • What is BioDelivery Sciences International revenue?

    Latest BioDelivery Sciences International annual revenue is $111.4 m.

  • What is BioDelivery Sciences International revenue per employee?

    Latest BioDelivery Sciences International revenue per employee is $679.2 k.

  • Who are BioDelivery Sciences International competitors?

    Competitors of BioDelivery Sciences International include Consort Medical, Jazz Pharmaceuticals and Bausch Health Companies.

  • Where is BioDelivery Sciences International headquarters?

    BioDelivery Sciences International headquarters is located at 4131 Parklake Ave #225, Raleigh.

  • Where are BioDelivery Sciences International offices?

    BioDelivery Sciences International has an office in Raleigh.

  • How many offices does BioDelivery Sciences International have?

    BioDelivery Sciences International has 1 office.